RxDoctor Payments Data

Komal Rastogi, MD

Neurology · West Valley City, UTNPI 1063774669

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,268 of the $9,168 with a category attached, or 79.3%. It is spread thinly across 59 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.

$9,168in general payments, 2019–2025

Across 359 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Medtronic$1K
  • AbbVie$808
  • Argenx US, Inc.$581
  • EMD Serono, Inc.$530
  • UCB, Inc.$462
  • plus $4K from 53 others

What the payments were for

  • Consulting fees$2132%
  • Travel & lodging$1,56917%
  • Food & beverage$7,26879%
  • Education$991%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.29$1,627
Medtronic12$1,079
AbbVie(2 entities)44$808
Argenx US, Inc.22$581
EMD Serono, Inc.29$530
UCB, Inc.19$462
TG Therapeutics, Inc.10$276
Acadia Pharmaceuticals Inc13$266
Sanofi10$228
Lundbeck LLC13$221
Takeda Pharmaceuticals U.S.A., Inc.5$218
AstraZeneca(2 entities)11$214
Immedica Pharma US, Inc.1$213
Bristol Myers Squibb11$212
Genentech USA, Inc.9$154
SK Life Science, Inc.7$142
Lilly USA, LLC9$131
Johnson & Johnson(2 entities)3$131
Biogen5$120
Boston Scientific13$119
Neurocrine Biosciences, Inc.6$101
Supernus Pharmaceuticals, Inc.7$93
Amneal Pharmaceuticals LLC5$93
Jazz Pharmaceuticals Inc.5$79
Adamas Pharmaceuticals, Inc.4$77
Merz Pharmaceuticals, LLC3$68
Neurelis, Inc.4$67
Pfizer4$61
Amgen3$58
Novartis3$58
Biodelivery Sciences International, Inc.4$53
Impel Pharmaceuticals Inc.3$46
Catalyst Pharmaceuticals, Inc.2$45
Abbott2$43
Cycle Pharmaceuticals Inc2$38
RGH Enterprises LLC1$38
Strongbridge US Inc.2$36
GE HealthCare2$33
Redhill Biopharma Inc.2$26
MDD US Operations, LLC1$25
E.r. Squibb & Sons, L.L.C.1$21
Welch Allyn1$19
Xeris Pharmaceuticals, Inc.1$19
Eisai Inc.1$19
Banner Life Sciences, LLC1$18
Collegium Pharmaceutical, Inc.1$18
Teva Pharmaceuticals USA, Inc.1$17
Inspire Medical Systems, Inc.1$17
Zyla Life Sciences, Inc.1$17
Grifols USA, LLC1$17
Avanir Pharmaceuticals, Inc.1$16
Ferring Pharmaceuticals Inc.1$15
Averitas Pharma Inc.1$14
Biohaven Pharmaceutical Holding Company Ltd.1$13
Teleflex LLC1$13
Biohaven Pharmaceuticals, Inc.1$13
Intuitive Surgical1$12
Sumitomo Pharma America, Inc.1$11
Portola Pharmaceuticals, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,168 in reported general payments places this provider in the 75th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Medicare billing

Part B allowed, 2024
$119,882
Medicare patients
433
Services billed
1,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a13$124,714
UbrelvyUbrogepant13$15,448
Emgality PenGalcanezumab-Gnlm13$11,923
Aimovig AutoinjectorErenumab-Aooe13$11,438
Memantine Hcl178$6,955
Propranolol Hcl ErPropranolol Hcl79$4,865
Carbidopa-LevodopaCarbidopa/Levodopa183$4,372
Lacosamide30$4,354
Primidone102$3,991
Levetiracetam126$3,732
Gabapentin95$3,324
Donepezil Hcl258$3,114
FingolimodFingolimod Hcl14$2,961
Topiramate129$2,846
Lamotrigine87$2,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$120$124,71413 claims
AbbVieUbrelvy$808$15,44813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 157 neurology providers in Utah.

Other neurology in West Valley City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →